The offer represents a premium of 54% to Endocyte's closing price of $US15.56 on Wednesday.
Until the deal is finalised, Endocyte will continue to operate as a separate and independent company.
"We are thrilled that Novartis recognizes the potential for Lu-PSMA-617 to change the treatment landscape for men with metastatic castration-resistant prostate cancer (mCRPC), as well as the broader role that RLTs may potentially play in the treatment of cancer", said Mike Sherman, president and CEO of Endocyte.
"Note a below-average reaction time at the business development department considering that the Endocyte market cap was at $110 million only 12 months ago", Baader Helvea's Bruno Bulic said.
The transaction is subject to customary closing conditions, including the approval of Endocyte's stockholders and receipt of regulatory approvals. Novartis has also boosted its revenue outlook for the year, noting that it expects a low to mid-single digit rate of growth.
Make Ramsey Arsenal captain, don't let him leave - Wilshere
The Gunners host Leicester on Monday night before facing Sporting Lisbon in Portugal on Thursday and Crystal Palace the following Sunday.
Mourinho: I'd love to have Hazard at Manchester United
They are doing well in the Champions League, so they have the opportunity to improve in the Premier League. Hazard is expecting to be on the end of some rough treatment from United's players at Stamford Bridge .
Apple's iPhone XR Pre-Orders Go Live in Canada
Earlier this week, Apple confirmed that its new iPhone XR model will launch for preorder at 12:01AM Pacific on October 19. As for Airtel, the iPhone XR can be booked via the telecom giant from today with down payments starting at Rs. 14,999.
By 1410 BST, Novartis shares were 1.83% higher at CHF85.82. Under the terms of the agreement and plan of merger, upon closing, holders of Endocyte common stock would receive Dollars 24 in cash per share.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products.
Endocyte's knowledge and abilities will help Novartis in its development of a drug that can be used earlier in the treatment of prostate cancer.
Since taking over in February, Narasimhan has shed over-the-counter medicines and generic pills while pushing a spinoff of Novartis's Alcon eyecare unit come 2019. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies.
Another company developing drugs that deliver targeted radiotherapies is New York-based Actinium Pharmaceuticals.